The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 110-118

  Dasbach, Erik J ^a   Nagy, Laszlo ^b   Brandtmller, Agnes ^c   Elbasha, Elamin H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD   (Hungary)

^c Consultant to MSD ^*  (Hungary)

Author keywords

Cervical intraepithelial neoplasia; Cost effectiveness analysis; Epidemiology; Human papillomavirus; Uterine cervical neoplasms; Vaccines

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; HUNGARY; MATHEMATICAL MODEL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HUNGARY; IMMUNIZATION PROGRAMS; INCIDENCE; MODELS, ECONOMIC; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 77149121464     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903546013     Document Type: Article

References (38)

1. World Health Organization (WHO). Vaccinating against cervical cancer. Bull World Health Organ 2007;85:89-90.
2. Parkin M, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55: 244-265.
4. Walboomers JM, Jacobs MV Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
5. De Villiers EM, Fauquet C, Broker TR, et al. Classifications of papillomaviruses. Virology 2004;324:17-27.
6. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006;61(6 Suppl 1):S3-14.
7. Denny L, Kuhn L, De Souza M, et al. Screen-and treat approaches for cervical cancer prevention in low-resource settings. JAMA 2005;294:2173-2181.
8. Arbyn M, Raifu AO, Autier P, et al. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-1715.
9. International Agency for Research on Cancer (IARC). IARC Handbook of Cancer Prevention. Volume 10, Cervix Cancer Screening. Lyon: IARC press, 2004.
10. Hungarian National Cancer Control Programme (HNCCP). Available at: http://www.cancerworld.org/cancerworldadmin/getStaticModFile.aspx?id=1683. Accessed November 24, 2007.
11. Boncz I, Sebestyén A, Döbrossy L, et al. [The coverage of cervical screening in Hungary]. Orvosi Hetilap 2007;148:2177-2182.
12. Trimble CL, Genkinger JM, Burke AE, et al. Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol 2005;105:174-81.
13. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213-227.
14. Kornya L, Cseh I, Deak J, et al. The diagnostics and prevalence of genital human papillomavirus (HPV) infection in Hungary. Eur J Obstet Gynecol Reprod Biol 2002;100:231-236.
15. Deák J, Cseh I, Szöllösi J, et al. [Detection of human papillomavirus infection by the nucleic acid hybridization method (a multicenter study)]. Orvosi Hetilap 1999;140:115-120.
16. NIB Research. Nordic survey, Hungary 2004: Personal interview with 300 women (representative between the ages of 16-45). Unpublished Merck Sharp & Dohme survey, 2004. Data are available from MSD Hungary local database.
17. National Health Insurance Fund Administration (NHIFA). http://www.oep.hu. Accessed November 28, 2007.
18. European Agency for the Evaluation of Medicinal Products (EMEA). (2006) European Public Assessment Report (EPAR). Available at: http://www.emea.europa. eu/humandocs/PDFs/EPAR/silgard/073206en6.pdf. Accessed October 30, 2007.
19. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007;85:719-726.
20. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13: 28-41.
21. Issues & Answers. Drivers and barriers to HPV vaccination among consumers in strategic Merck vaccine international Markets. Unpublished Merck Sharp & Dohme data. Apr/May 2004.
22. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007;27:414-422.
23. Elbasha EH, Galvani. Vaccination against multiple HPV types. Math Biosci 2005;197:88-117.
24. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine 2007;26:128-139.
25. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-15. Epub 2007 March 16.
26. Muñoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.
27. Kulsingham SL, Benard D, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008;6:4 [Epub ahead of print].
28. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244-251.
29. Gulácsi L. The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience. Eur J Health Econ 2007;8:83-88.
30. World Health Organization (WHO). Threshold values for intervention cost-effectiveness by region. Available at: http://www.who.int/choice/costs/CER- levels/en/index.html. Accessed November 20, 2007.
31. Central Intelligence Agency. The World Factbook - Hungary. Available at: https://www.cia.gov/library/publications/the-world-factbook/print/hu.html. Accessed November 25, 2007.
32. Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry. Tufts-New England Medical Center, ICRHPS, 2006. Available at: http://www.tufts-nemc.org/cearegistry/data/docs/ PhaseIIIACompleteLeagueTable.pdf. Accessed November 26, 2007.
33. Health Protection Agency. Diagnoses and rates of selected STIs seen at GUM clinics, United Kingdom: 2000-2004. National, Regional and Strategic Health Authority Summary Tables. Available at: http://www.hpa.org.uk/infections/topics- az/hiv-and-sti/epidemiology/datatables2004.htm. Accessed September 09, 2007.
34. Brown DR, Kjaer SK, Sigurdsson K, et al. The Impact of quadrivalent human papillomavirus (HPV; 6, 11, 16, 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-935.
35. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61:1934-1340.
36. Hobbs CG, Sterne JA, Bailey M, et al. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006;31:259-266.
37. Freed GL, Derkay CS. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int J Pediatr Otorhinolaryngol 2006;70:1799-1803.
38. Acs N, Brandtmüller Á, Nagy L, et al. Cost of cervix cancer treatment in Hungary. Eur J Health Econ 2006;7(Suppl 1) (Abstracts, 6th European Conference on Health Economics, 2006, 6-9 July, Budapest, Hungary).